ERAS Program for Hepatic Resection Decreased Postoperative Complications
The effect of compliance with ERAS protocols on postoperative adverse events and length of hospital stay was evaluated in a single-center cohort study.
Hepatocellular Carcinoma
Sintilimab Plus IBI305 for Hepatitis B Virus-Positive Hepatocellular Carcinoma
The combination of sintilimab and IBI305 improved progression-free survival in patients with unresectable hepatocellular carcinoma.
Donafenib Bests Sorafenib in Chinese Patients With Advanced Hepatocellular Carcinoma
Overall survival was superior with donafenib.
Atezolizumab Plus Bevacizumab for Advanced Hepatocellular Carcinoma Showed Better Improvement in Patient-Reported Outcomes
Patient reported outcomes for quality of life, emotional and social functioning, and general disease symptoms were better with atezolizumab/bevacizumab compared with sorafenib monotherapy.
SIRT Is More Cost-Effective Than Sorafenib in Locally Advanced HCC
Investigators compared the cost-effectiveness of selective internal radiotherapy (SIRT) of that of sorafenib in the locally advanced hepatocellular carcinoma setting.
Study Data Suggest Role for Lenvatinib in Unresectable HCC With Child-Pugh B Liver Function
Outcomes of lenvatinib-receiving patients who progressed to Child-Pugh B liver function within the first 8 weeks of treatment were compared with those of patients who maintained Child-Pugh A classification during the same time period.
Tivozanib and Durvalumab Doublet Regimen Is Well-Tolerated in HCC
Combination tivozanib and durvalumab was found to be well-tolerated in patients with advanced, treatment-naïve hepatocellular carcinoma (HCC).
Value of Follow-Up Chest Computed Tomography in the Surveillance of Patients with Hepatocellular Carcinoma
[Journal of Hepatocellular Carcinoma] Researchers at UT MD Anderson Cancer Center assessed the value of chest, abdominal, and pelvic CT in the surveillance of patients with HCC, and the potential drawbacks to the practice.
Severe Fatigue is an Important Factor in the Prognosis of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib
[Cancer Management and Research] Researchers present a simple classification method for assessing fatigue, which is proven to be a prognostic marker of TTP and OS in patients with HCC.
FDA Denies Accelerated Approval of Keytruda Plus Lenvima for Unresectable HCC
In the CRL, the FDA stated that the data from KEYNOTE-524/Study 116 did not demonstrate a meaningful advantage over available therapies for unresectable or metastatic HCC.
- Loading...
Loading...
Next post in Liver Cancer
Loading... 
Loading...